Crossmark

Prospective feasibility study of neoadjuvant dose-dense paclitaxel plus carboplatin with bevacizumab therapy followed by interval debulking surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer patients

Crossref DOI link: https://doi.org/10.1007/s10147-021-02050-3

Published Online: 2021-10-14

Published Print: 2022-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Iwasa-Inoue, Naomi

Nomura, Hiroyuki https://orcid.org/0000-0001-8996-4284
Kataoka, Fumio

Chiyoda, Tatsuyuki

Yoshihama, Tomoko

Nanki, Yoshiko

Sakai, Kensuke

Kobayashi, Yusuke

Yamagami, Wataru

Morisada, Tohru

Hirasawa, Akira

Aoki, Daisuke
Funding

Funding for this research was provided by:

Japan Society for the Promotion of Science (JP18K09297)
License Information

Text and Data Mining valid from 2021-10-14

Version of Record valid from 2021-10-14
More Information

Article History

Received: 22 February 2021

Accepted: 5 October 2021

First Online: 14 October 2021

Declarations

:

: Hiroyuki Nomura reports grants from Japan Society for the Promotion of Science, during the conduct of the study. All other authors declare that they have no conflicts of interest.

Document is current

Any future updates will be listed below